These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 1564128)
21. Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Wyvill KM; Flora KP; Broder S; Johns DG Clin Pharmacol Ther; 1991 Sep; 50(3):278-85. PubMed ID: 1914362 [TBL] [Abstract][Full Text] [Related]
22. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Dolin R; Lambert JS; Morse GD; Reichman RC; Plank CS; Reid J; Knupp C; McLaren C; Pettinelli C Rev Infect Dis; 1990; 12 Suppl 5():S540-9; discussion S549-51. PubMed ID: 1974726 [TBL] [Abstract][Full Text] [Related]
23. Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS. Burger D; Meenhorst P; Mulder J; Henrichs J; Frissen J; Kroon F; ten Napel C; Koks K; Bult A; Beijnen J J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):163-8. PubMed ID: 7552480 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. Ray GF; Mason WD; Badr MZ Drug Metab Dispos; 1990; 18(5):654-8. PubMed ID: 1981715 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. Hoetelmans RM; van Heeswijk RP; Profijt M; Mulder JW; Meenhorst PL; Lange JM; Reiss P; Beijnen JH AIDS; 1998 Dec; 12(17):F211-6. PubMed ID: 9863862 [TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974 [TBL] [Abstract][Full Text] [Related]
27. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Anderson BJ; Pons G; Autret-Leca E; Allegaert K; Boccard E Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918 [TBL] [Abstract][Full Text] [Related]
28. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients. Rozencweig M; McLaren C; Beltangady M; Ritter J; Canetta R; Schacter L; Kelley S; Nicaise C; Smaldone L; Dunkle L Rev Infect Dis; 1990; 12 Suppl 5():S570-5. PubMed ID: 2166965 [TBL] [Abstract][Full Text] [Related]
29. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis. Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026 [TBL] [Abstract][Full Text] [Related]
30. Didanosine once daily: an overview. Youle M Antivir Ther; 1998; 3 Suppl 4():35-7. PubMed ID: 10723507 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. Dudley MN; Graham KK; Kaul S; Geletko S; Dunkle L; Browne M; Mayer K J Infect Dis; 1992 Sep; 166(3):480-5. PubMed ID: 1323615 [TBL] [Abstract][Full Text] [Related]
32. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model. Lobo ED; Robertson-Plouch C; Quinlan T; Hong Q; Bergstrom RF Paediatr Drugs; 2010 Jun; 12(3):201-11. PubMed ID: 20297865 [TBL] [Abstract][Full Text] [Related]
33. Didanosine therapy in patients intolerant of or failing zidovudine therapy. Rathbun RC; Martin ES Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. Knupp CA; Brater DC; Relue J; Barbhaiya RH J Clin Pharmacol; 1993 Oct; 33(10):912-7. PubMed ID: 8227460 [TBL] [Abstract][Full Text] [Related]
36. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Shelton MJ; Adams JM; Hewitt RG; Steinwandel C; DeRemer M; Cousins S; Morse GD Pharmacotherapy; 1997; 17(3):438-44. PubMed ID: 9165548 [TBL] [Abstract][Full Text] [Related]
37. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Conte JE; Golden JA; Kipps JE; Lin ET; Zurlinden E Clin Pharmacokinet; 2004; 43(6):395-404. PubMed ID: 15086276 [TBL] [Abstract][Full Text] [Related]
38. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Variol P; Nguyen L; Tranchand B; Puozzo C Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069 [TBL] [Abstract][Full Text] [Related]
39. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Hodges TL; Kahn JO; Kaplan LD; Groopman JE; Volberding PA; Amman AJ; Arri CJ; Bouvier LM; Mordenti J; Izu AE Antimicrob Agents Chemother; 1991 Dec; 35(12):2580-6. PubMed ID: 1810192 [TBL] [Abstract][Full Text] [Related]
40. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial. Drusano GL; Yuen GJ; Lambert JS; Seidlin M; Dolin R; Valentine FT Ann Intern Med; 1992 Apr; 116(7):562-6. PubMed ID: 1347442 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]